Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example (Q46394309)

21 December 2017

http://europepmc.org/abstract/MED/25114058

title

Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example (English)

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

1 reference

Désirée van der Heijde

9

Désirée van der Heijde

0 references

Paul Emery

4

Paul Emery

0 references

Maxime Dougados

5

Maxime Dougados

1 reference

21 December 2017

2

Josef S Smolen

1 reference

21 December 2017

7

Daniel Aletaha

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

Michael E Weinblatt

3

Michael E Weinblatt

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

Robert Landewé

1

Robert B M Landewé

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

Roy Fleischmann

6

Roy Fleischmann

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

Arthur Kavanaugh

8

Arthur Kavanaugh

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

language of work or name

English

0 references

publication date

11 August 2014

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

published in

Annals of the Rheumatic Diseases

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

volume

73

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

issue

10

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

page(s)

1755-1760

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

cites work

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Proposal for a new nomenclature of disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Therapies for active rheumatoid arthritis after methotrexate failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Reporting noninferiority trials--reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Comparative effectiveness research: a report from the Institute of Medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

10.1136/ANNRHEUMDIS-2014-205821

21 January 2018

Identifiers

DOI

1 reference

21 December 2017

http://europepmc.org/abstract/MED/25114058

Dimensions Publication ID

1005830202

0 references

1 reference

21 December 2017